

BP-50636

Gresonitamab -Anti CLDN18.2/CD3 Bispecific Antibody

Gresonitamab (AMG 910) is an experimental half-life extended (HLE) bispecific T-cell engager (BiTE) antibody designed to treat cancers that overexpress Claudin-18.2. By simultaneously binding to CD3-positive T-cells and CLDN18.2-expressing tumor cells, it aims to redirect the immune system to actively target and destroy cancer cells.

Product Details	
Species Reactivity	Human
Source	Mammalian Cells
Isotype	(scFv-heavy-kappa)-(scFv-heavy-lambda)-scFc
Class	Anti-Human Bispecific antibodies
Type	Recombinant Humanized
Clone	SP34-2/OKT3
Target	Anti-human CLDN18.2/CD3
Purity	>99%
Molecular Weight	106 kDa
CAS Number	2413817-97-5
Formulation	NA
Storage conditions	Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws.